Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com

ELI LILLY & Co

Statements

Graphics

g120317g32y59.jpgg120317g91z99.jpg
NotesSupport
aboutterms
2.2.0.25truefalse40404 - Disclosure - Collaborations (Details)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009 USD ($) USD ($) / shares $Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit15Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008 USD ($) USD ($) / shares $Duration_1_1_2008_To_12_31_2008http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit15Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalsetruefalse{us-gaap_StatementGeographicalAxis} : United States [Member] {us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Research and Development Expense [Member] {us-gaap_ProductOrServiceAxis} : Necitumumab [Member] 1/1/2010 - 3/31/2010 Duration_1_1_2010_To_3_31_201025http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseUnited States [Member]us-gaap_StatementGeographicalAxisxbrldihttp://xbrl.org/2006/xbrldilly_UnitedStatesMemberus-gaap_StatementGeographicalAxisexplicitMemberfalsefalseResearch and Development Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ResearchAndDevelopmentExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseNecitumumab [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_NecitumumabMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli05falsefalsetruefalse{us-gaap_StatementGeographicalAxis} : Outside the United States [Member] {us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Research and Development Expense [Member] {us-gaap_ProductOrServiceAxis} : Necitumumab [Member] 1/1/2010 - 3/31/2010 Duration_1_1_2010_To_3_31_201024http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseOutside the United States [Member]us-gaap_StatementGeographicalAxisxbrldihttp://xbrl.org/2006/xbrldilly_OutsideUnitedStatesMemberus-gaap_StatementGeographicalAxisexplicitMemberfalsefalseResearch and Development Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ResearchAndDevelopmentExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseNecitumumab [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_NecitumumabMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli06falsefalsetruefalse{us-gaap_ProductOrServiceAxis} : Exenatide [Member] {us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Sales NEW [Member] 1/1/2010 - 12/31/2010 Duration_1_1_2010_To_12_31_20108http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseExenatide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseSales NEW [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_SalesNewMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli07falsefalsetruefalse{us-gaap_ProductOrServiceAxis} : Exenatide [Member] {us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Gross Margin Share [Member] 1/1/2010 - 12/31/2010 Duration_1_1_2010_To_12_31_20105http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseExenatide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGross Margin Share [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_GrossMarginShareMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli08falsefalsetruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Profit and Development and Marketing Share [Member] {us-gaap_ProductOrServiceAxis} : Effient [Member] 7/1/2010 - 9/30/2010 Duration_7_1_2010_To_9_30_2010http://www.sec.gov/CIK0000059478duration2010-07-01T00:00:002010-09-30T00:00:00falsefalseProfit and Development and Marketing Share [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ProfitAndDevelopmentAndMarketingShareMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseEffient [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_EffientMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli09falsefalsetruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Profit and Development and Marketing Share [Member] {us-gaap_ProductOrServiceAxis} : Effient [Member] 1/1/2010 - 12/31/2010 Duration_1_1_2010_To_12_31_20106http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseProfit and Development and Marketing Share [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ProfitAndDevelopmentAndMarketingShareMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseEffient [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_EffientMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli010falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Selling and Marketing Expense [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_20103http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSelling and Marketing Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SellingAndMarketingExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Selling and Marketing Expense [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_20093http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSelling and Marketing Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SellingAndMarketingExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Selling and Marketing Expense [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20084http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSelling and Marketing Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SellingAndMarketingExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13falsefalsetruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Selling and Marketing Expense [Member] {us-gaap_ProductOrServiceAxis} : Necitumumab [Member] 1/1/2010 - 3/31/2010 Duration_1_1_2010_To_3_31_201023http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseSelling and Marketing Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SellingAndMarketingExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseNecitumumab [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_NecitumumabMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli014falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Prepaid Selling and Marketing Expense [Member] {us-gaap_ProductOrServiceAxis} : Duloxetine BI [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_20103http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-03-31T00:00:00falsefalsePrepaid Selling and Marketing Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_PrepaidSellingAndMarketingExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseDuloxetine BI [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_DuloxetineBiMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15falsefalsetruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Research and Development Expense [Member] {us-gaap_ProductOrServiceAxis} : Necitumumab [Member] 1/1/2010 - 3/31/2010 Duration_1_1_2010_To_3_31_201022http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseResearch and Development Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ResearchAndDevelopmentExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseNecitumumab [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_NecitumumabMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli016falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Research and Development Expense [Member] {us-gaap_ProductOrServiceAxis} : Semagacestat [Member] 7/1/2010 - 9/30/2010 USD ($) $Duration_7_1_2010_To_9_30_20102http://www.sec.gov/CIK0000059478duration2010-07-01T00:00:002010-09-30T00:00:00falsefalseResearch and Development Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ResearchAndDevelopmentExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseSemagacestat [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_SemagacestatMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalsetruefalse{us-gaap_ProductOrServiceAxis} : Exenatide [Member] {us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Research and Development and Marketing and Selling Expense [Member] 1/1/2010 - 12/31/2010 Duration_1_1_2010_To_12_31_20107http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseExenatide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseResearch and Development and Marketing and Selling Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_ResearchAndDevelopmentAndMarketingAndSellingExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli018falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Capital Expense [Member] {us-gaap_ProductOrServiceAxis} : Exenatide Once Weekly [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20085http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseCapital Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_CapitalExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseExenatide Once Weekly [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideOnceWeeklyMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19falsefalsetruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Capital Expense [Member] {us-gaap_ProductOrServiceAxis} : Exenatide Once Weekly Pen [Member] 1/1/2008 - 12/31/2008 Duration_1_1_2008_To_12_31_200810http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseCapital Expense [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_CapitalExpenseMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseExenatide Once Weekly Pen [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideOnceWeeklyPenMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli020falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Milestone Payments [Member] {us-gaap_ProductOrServiceAxis} : Necitumumab [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_20102http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseMilestone Payments [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_MilestonePaymentsMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseNecitumumab [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_NecitumumabMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Milestone Payments [Member] {us-gaap_ProductOrServiceAxis} : TPG-Axon [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20089http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseMilestone Payments [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_MilestonePaymentsMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseTPG-Axon [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_TpgAxonMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22falsefalseEURtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Milestone Payments [Member] {us-gaap_ProductOrServiceAxis} : BI compounds [Member] 1/1/2011 - 3/31/2011 EUR (€) €Duration_1_1_2011_To_3_31_20112http://www.sec.gov/CIK0000059478duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseMilestone Payments [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_MilestonePaymentsMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseBI compounds [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_BiCompoundsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/iso4217EURiso42170EUREUR€23falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Milestone Payments [Member] {us-gaap_ProductOrServiceAxis} : LLY compounds [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_201122http://www.sec.gov/CIK0000059478duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseMilestone Payments [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_MilestonePaymentsMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseLLY compounds [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_LlyCompoundsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Milestone Payments [Member] {us-gaap_ProductOrServiceAxis} : LLY optional compound [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011222http://www.sec.gov/CIK0000059478duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseMilestone Payments [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_MilestonePaymentsMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseLLY optional compound [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_LlyOptionalCompoundMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25falsefalseUSDtruefalse{us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis} : Loan Commitment [Member] {us-gaap_ProductOrServiceAxis} : Exenatide Once Weekly [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20088http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseLoan Commitment [Member]us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisxbrldihttp://xbrl.org/2006/xbrldilly_LoanCommitmentMemberus-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxisexplicitMemberfalsefalseExenatide Once Weekly [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideOnceWeeklyMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Erbitux [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_20109http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseErbitux [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ErbituxMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$27falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Erbitux [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_2009105http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseErbitux [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ErbituxMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$28falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Erbitux [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200815http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseErbitux [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ErbituxMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$29falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Exenatide [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201010http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseExenatide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$30falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Exenatide [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_2009106http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseExenatide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$31falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Exenatide [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_200816http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseExenatide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$32falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Exenatide Once Weekly [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20086http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseExenatide Once Weekly [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideOnceWeeklyMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$33falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Exenatide Once Weekly Pen [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_20104http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseExenatide Once Weekly Pen [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideOnceWeeklyPenMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$34falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Exenatide Once Weekly Pen [Member] 1/1/2008 - 12/31/2008 USD ($) $Duration_1_1_2008_To_12_31_20087http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseExenatide Once Weekly Pen [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ExenatideOnceWeeklyPenMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$35falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Effient [Member] 1/1/2010 - 12/31/2010 USD ($) $Duration_1_1_2010_To_12_31_201042http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseEffient [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_EffientMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$36falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Effient [Member] 1/1/2009 - 12/31/2009 USD ($) $Duration_1_1_2009_To_12_31_200920http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseEffient [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_EffientMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$37falsefalseEURtruefalse{us-gaap_ProductOrServiceAxis} : Boerhringer Ingelheim (BI) [Member] 1/1/2011 - 3/31/2011 EUR (€) €Duration_1_1_2011_To_3_31_2011http://www.sec.gov/CIK0000059478duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseBoerhringer Ingelheim (BI) [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_BoerhringerIngelheimBiMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/iso4217EURiso42170EUREUR€5false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2244220000022442.2falsetruefalsefalsefalse2truefalsefalse2117150000021171.5falsetruefalsefalsefalse3truefalsefalse1992580000019925.8falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26truefalsefalse7190000071.9falsetruefalsetruefalse27truefalsefalse9250000092.5falsetruefalsetruefalse28truefalsefalse27000002.7falsetruefalsetruefalse29truefalsefalse168100000168.1falsetruefalsetruefalse30truefalsefalse147700000147.7falsetruefalsetruefalse31truefalsefalse9670000096.7falsetruefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35truefalsefalse115000000115.0falsetruefalsetruefalse36truefalsefalse2700000027.0falsetruefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse6false0us-gaap_OtherSalesRevenueNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse633800000633.8falsefalsefalsefalsefalse2truefalsefalse664500000664.5falsefalsefalsefalsefalse3truefalsefalse446100000446.1falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26truefalsefalse314200000314.2falsefalsefalsetruefalse27truefalsefalse298300000298.3falsefalsefalsetruefalse28truefalsefalse2670000026.7falsefalsefalsetruefalse29truefalsefalse262500000262.5falsefalsefalsetruefalse30truefalsefalse300800000300.8falsefalsefalsetruefalse31truefalsefalse299400000299.4falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryRevenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse7false0us-gaap_Revenuesus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsetotallabel1truefalsefalse2307600000023076.0falsefalsefalsefalsefalse2truefalsefalse2183600000021836.0falsefalsefalsefalsefalse3truefalsefalse2037190000020371.9falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26truefalsefalse386100000386.1falsefalsefalsetruefalse27truefalsefalse390800000390.8falsefalsefalsetruefalse28truefalsefalse2940000029.4falsefalsefalsetruefalse29truefalsefalse430600000430.6falsefalsefalsetruefalse30truefalsefalse448500000448.5falsefalsefalsetruefalse31truefalsefalse396100000396.1falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 truefalse8false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse48842000004884.2falsefalsefalsefalsefalse2truefalsefalse43265000004326.5falsefalsefalsefalsefalse3truefalsefalse38409000003840.9falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse8000000080.0falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 falsefalse9false0lly_CollaborativeArrangementIncomeStatementClassificationAndAmountsllyfalsedebitdurationDefinition: Income statement classification and amounts attributable to transactions arising from the collaborative...falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10truefalsefalse174500000174.5falsefalsefalsetruefalse11truefalsefalse319200000319.2falsefalsefalsetruefalse12truefalsefalse307600000307.6falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryDefinition: Income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants for each period an income statement is presented.No authoritative reference available.falsefalse10false0lly_CollaborativeArrangementNatureAndPurposeNewllyfalsedebitdurationLabel: Collaborative Arrangement, Nature and Purpose Element ID: us-gaap_CollaborativeArrangementNatureAndPurpose Balance...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18truefalsefalse550000000550falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryLabel: Collaborative Arrangement, Nature and Purpose Element ID: us-gaap_CollaborativeArrangementNatureAndPurpose Balance Type: na Data Type: MONETARY Period Type: duration --------------------------------------------------------------------- Definition: Description of nature and purpose of collaborative arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-1 -Paragraph 21 -Subparagraph aNo authoritative reference available.falsefalse11false0lly_CollaborativeArrangementRightsAndObligationsNewllyfalsedebitdurationLabel: Collaborative Arrangement, Rights and Obligations Element ID:...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse125000000125.0falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse400000000400.0falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20truefalsefalse250000000250.0falsefalsefalsetruefalse21truefalsefalse7000000070.0falsefalsefalsetruefalse22truefalsefalse625000000625.0falsefalsefalsetruefalse23truefalsefalse650000000650.0falsefalsefalsetruefalse24truefalsefalse525000000525.0falsefalsefalsetruefalse25truefalsefalse165000000165.0falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32truefalsefalse125000000125.0falsefalsefalsetruefalse33truefalsefalse9000000090.0falsefalsefalsetruefalse34truefalsefalse130000000130.0falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryLabel: Collaborative Arrangement, Rights and Obligations Element ID: us-gaap_CollaborativeArrangementRightsAndObligations Balance Type: na Data Type: MONETARY Period Type: duration --------------------------------------------------------------------- Definition: Description of rights and obligations under the collaborative arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-1 -Paragraph 21 -Subparagraph bNo authoritative reference available.falsefalse12false0lly_CollaborativeArrangementRightsAndObligationsPercentllyfalsenadurationDescription of rights and obligations under the collaborative arrangements - percent share in various revenues and costs.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4truetruefalse0.450.45falsefalsefalsetruefalse5truetruefalse0.7250.725falsefalsefalsetruefalse6truetruefalse11falsefalsefalsetruefalse7truetruefalse0.50.5falsefalsefalsetruefalse8truetruefalse0.50.5falsefalsefalsetruefalse9truetruefalse0.50.5falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11falsetruefalse00falsefalsefalsetruefalse12falsetruefalse00falsefalsefalsetruefalse13truetruefalse0.50.5falsefalsefalsetruefalse14falsetruefalse00falsefalsefalsetruefalse15truetruefalse0.450.45falsefalsefalsetruefalse16falsetruefalse00falsefalsefalsetruefalse17truetruefalse0.50.5falsefalsefalsetruefalse18falsetruefalse00falsefalsefalsetruefalse19truetruefalse0.60.6falsefalsefalsetruefalse20falsetruefalse00falsefalsefalsetruefalse21falsetruefalse00falsefalsefalsetruefalse22falsetruefalse00falsefalsefalsetruefalse23falsetruefalse00falsefalsefalsetruefalse24falsetruefalse00falsefalsefalsetruefalse25falsetruefalse00falsefalsefalsetruefalse26falsetruefalse00falsefalsefalsetruefalse27falsetruefalse00falsefalsefalsetruefalse28falsetruefalse00falsefalsefalsetruefalse29falsetruefalse00falsefalsefalsetruefalse30falsetruefalse00falsefalsefalsetruefalse31falsetruefalse00falsefalsefalsetruefalse32falsetruefalse00falsefalsefalsetruefalse33falsetruefalse00falsefalsefalsetruefalse34falsetruefalse00falsefalsefalsetruefalse35falsetruefalse00falsefalsefalsetruefalse36falsetruefalse00falsefalsefalsetruefalse37falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureDescription of rights and obligations under the collaborative arrangements - percent share in various revenues and costs.No authoritative reference available.falsefalse13false0lly_AcquiredInProcessResearchAndDevelopmentllyfalsedebitdurationThe amount of purchased research and development assets that are acquired in a business combination and/or licensing...falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse5000000050.0falsetruefalsefalsefalse2truefalsefalse9000000090.0falsetruefalsefalsefalse3truefalsefalse48354000004835.4falsetruefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37truefalsefalse300000000300.0falsetruefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of purchased research and development assets that are acquired in a business combination and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition.No authoritative reference available.falsefalse379Collaborations (Details)HundredThousandsUnKnownUnKnownUnKnowntruetrue